Tracking a preventive Drug's Real-World impact on rare swelling disorder
NCT ID NCT05469789
Summary
This study aims to see how well the preventive drug lanadelumab works for people with hereditary angioedema (HAE) in real-world UK clinics. It will compare how many HAE attacks participants had in the year before starting the drug to the number they have in the two years after starting it. Researchers will also collect information on treatment patterns, quality of life, and healthcare use from about 50 patients already on this medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Barts Health NHS Trust
London, England, E1 1BB, United Kingdom
Conditions
Explore the condition pages connected to this study.